{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T11:15:50Z","timestamp":1787915750254,"version":"build-2784847793"},"reference-count":78,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004489","name":"Mitacs","doi-asserted-by":"publisher","award":["IT29500"],"award-info":[{"award-number":["IT29500"]}],"id":[{"id":"10.13039\/501100004489","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The emerging field of nanotechnology has paved the way for revolutionary advancements in drug delivery systems, with nanosystems emerging as a promising avenue for enhancing the therapeutic potential and the stability of various bioactive compounds. Among these, cannabidiol (CBD), the non-psychotropic compound of the Cannabis sativa plant, has gained attention for its therapeutic properties. Consequently, researchers have devoted significant efforts to unlock the full potential of CBD\u2019s clinical benefits, where various nanosystems and excipients have emerged to overcome challenges associated with its bioavailability, stability, and controlled release for its transdermal application. Therefore, this comprehensive review aims to explain CBD\u2019s role in managing acute inflammatory pain and offers an overview of the state of the art of existing delivery systems and excipients for CBD. To summarize this review, a summary of the cannabinoids and therapeutical targets of CBD will be discussed, followed by its conventional modes of administration. The transdermal route of administration and the current topical and transdermal delivery systems will also be reviewed. This review will conclude with an overview of in vivo techniques that allow the evaluation of the anti-inflammatory and analgesic potentials of these systems.<\/jats:p>","DOI":"10.3390\/ijms25115858","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T03:48:49Z","timestamp":1716868129000},"page":"5858","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Transdermal Delivery of Cannabidiol for the Management of Acute Inflammatory Pain: A Comprehensive Review of the Literature"],"prefix":"10.3390","volume":"25","author":[{"given":"\u00c8ve","family":"Lefebvre","sequence":"first","affiliation":[{"name":"Department of Mechanical Engineering, Polytechnique Montr\u00e9al, Montr\u00e9al, QC H3T 1J4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Tawil","sequence":"additional","affiliation":[{"name":"Qeen BioTechnologies, Gatineau, QC J9J 3K3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u2019Hocine","family":"Yahia","sequence":"additional","affiliation":[{"name":"Department of Mechanical Engineering, Polytechnique Montr\u00e9al, Montr\u00e9al, QC H3T 1J4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jconrel.2003.09.001","article-title":"Cannabidiol\u2014Transdermal Delivery and Anti-Inflammatory Effect in a Murine Model","volume":"93","author":"Lodzki","year":"2003","journal-title":"J. Control. Release"},{"key":"ref_2","unstructured":"World Health Organization (2024, May 13). Osteoarthritis. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/osteoarthritis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"103077","DOI":"10.1016\/j.amsu.2021.103077","article-title":"An up to Date on Clinical Prospects and Management of Osteoarthritis","volume":"72","author":"Maqbool","year":"2021","journal-title":"Ann. Med. Surg."},{"key":"ref_4","unstructured":"Benjamin, O., Goyal, A., and Lappin, S.L. (2023, October 11). Disease-Modifying Antirheumatic Drugs (DMARD), StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK507863."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.36076\/ppj.2008\/11\/S105","article-title":"Opioid Complications and Side Effects","volume":"11","author":"Benyamin","year":"2008","journal-title":"Pain Physician"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/BF03259279","article-title":"Corticosteroids in Rheumatoid Arthritis","volume":"3","author":"Bijlsma","year":"1995","journal-title":"Clin. Immunother."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Bindu, S., Mazumder, S., and Bandyopadhyay, U. (2020). Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Organ Damage: A Current Perspective. Biochem. Pharmacol., 180.","DOI":"10.1016\/j.bcp.2020.114147"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11926-009-0002-8","article-title":"The Use of Opioids in the Treatment of Osteoarthritis: When, Why, and How?","volume":"11","author":"Goodwin","year":"2009","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1001\/jama.2020.22171","article-title":"Diagnosis and Treatment of Hip and Knee Osteoarthritis","volume":"325","author":"Katz","year":"2021","journal-title":"JAMA"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Mrid, B.R., Bouchmaa, N., Ainani, H., El Fatimy, R., Malka, G., and Mazini, L. (2022). Anti-Rheumatoid Drugs Advancements: New Insights into the Molecular Treatment of Rheumatoid Arthritis. Biomed. Pharmacother., 151.","DOI":"10.1016\/j.biopha.2022.113126"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-3-030-21737-2_8","article-title":"Pharmacology of Medical Cannabis","volume":"1162","author":"Amin","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.tplants.2020.05.005","article-title":"Phytocannabinoids: Origins and Biosynthesis","volume":"25","year":"2020","journal-title":"Trends Plant Sci."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Pagano, C., Navarra, G., Coppola, L., Avilia, G., Bifulco, M., and Laezza, C. (2022). Cannabinoids: Therapeutic Use in Clinical Practice. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23063344"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11916-020-0835-4","article-title":"The Role of Cannabidiol (CBD) in Chronic Pain Management: An Assessment of Current Evidence","volume":"24","author":"Boyaji","year":"2020","journal-title":"Curr. Pain Headache Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jconrel.2021.05.005","article-title":"Delivering Therapeutic Cannabinoids via Skin: Current State and Future Perspectives","volume":"334","author":"Tijani","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Mahmoudinoodezh, H., Telukutla, S.R., Bhangu, S.K., Bachari, A., Cavalieri, F., and Mantri, N. (2022). The Transdermal Delivery of Therapeutic Cannabinoids. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14020438"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.biopsych.2015.07.028","article-title":"An Introduction to the Endogenous Cannabinoid System","volume":"79","author":"Lu","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e00682","DOI":"10.1002\/prp2.682","article-title":"Diversity of Molecular Targets and Signaling Pathways for CBD","volume":"8","author":"Almeida","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/bs.apha.2017.03.007","article-title":"CB 1 and CB 2 Receptor Pharmacology","volume":"80","author":"Howlett","year":"2017","journal-title":"Cannabinoid Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Mlost, J., Bryk, M., and Starowicz, K. (2020). Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228870"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Zou, S., and Kumar, U. (2018). Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19030833"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2174\/1570159X18666200720172624","article-title":"Phytocannabinoids: General Aspects and Pharmacological Potential in Neurodegenerative Diseases","volume":"19","author":"Smid","year":"2021","journal-title":"Curr. Neuropharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Nigro, E., Formato, M., Crescente, G., and Daniele, A. (2021). Cancer Initiation, Progression and Resistance: Are Phytocannabinoids from Cannabis sativa L. Promising Compounds?. Molecules, 26.","DOI":"10.3390\/molecules26092668"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"12663","DOI":"10.3390\/molecules181012663","article-title":"Understanding the Molecular Aspects of Tetrahydrocannabinol and Cannabidiol as Antioxidants","volume":"18","author":"Borges","year":"2013","journal-title":"Molecules"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Atalay, S., Jarocka-Karpowicz, I., and Skrzydlewska, E. (2019). Antioxidative and Anti-Inflammatory Properties of Cannabidiol. Antioxidants, 9.","DOI":"10.3390\/antiox9010021"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1007\/s00018-016-2300-4","article-title":"The CB2 Receptor and Its Role as a Regulator of Inflammation","volume":"73","author":"Turcotte","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2174\/157015907780866884","article-title":"The Cannabinoid CB2 Receptor as a Target for Inflammation-Dependent Neurodegeneration","volume":"5","author":"Ashton","year":"2007","journal-title":"Curr. Neuropharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The Diverse CB1and CB2receptor Pharmacology of Three Plant Cannabinoids: \u03949-Tetrahydrocannabinol, Cannabidiol and \u03949-Tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1124\/jpet.105.093500","article-title":"A Novel Cannabinoid Peripheral Cannabinoid Receptor-Selective Inverse Agonist Blocks Leukocyte Recruitment In Vivo","volume":"316","author":"Lunn","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1189\/jlb.3RU0115-021R","article-title":"Regulation of Inflammation by Cannabinoids, the Endocannabinoids 2-Arachidonoyl-Glycerol and Arachidonoyl-Ethanolamide, and Their Metabolites","volume":"97","author":"Turcotte","year":"2015","journal-title":"J. Leukoc. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pain.2008.04.006","article-title":"The Putative Cannabinoid Receptor GPR55 Plays a Role in Mechanical Hyperalgesia Associated with Inflammatory and Neuropathic Pain","volume":"139","author":"Staton","year":"2008","journal-title":"Pain"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"120582","DOI":"10.1016\/j.lfs.2022.120582","article-title":"Pharmacological Effects of Cannabidiol by Transient Receptor Potential Channels","volume":"300","author":"Etemad","year":"2022","journal-title":"Life Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3389\/fnmol.2018.00487","article-title":"Cannabinoid Ligands Targeting TRP Channels","volume":"11","author":"Muller","year":"2019","journal-title":"Front. Mol. Neurosci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/cmi.2014.99","article-title":"Ubiquitin-Mediated NF\u03baB Degradation Pathway","volume":"12","author":"Xu","year":"2014","journal-title":"Cell. Mol. Immunol."},{"key":"ref_35","unstructured":"Health Canada (2024, May 13). Review of Cannabidiol: Report of the Science Advisory Committee on Health Products Containing Cannabis. Canada. 28 July 2022. Available online: https:\/\/www.canada.ca\/en\/health-canada\/corporate\/about-health-canada\/public-engagement\/external-advisory-bodies\/health-products-containing-cannabis\/review-cannabidiol-health-products-containing-cannabis.html."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1517\/14656566.7.5.607","article-title":"Sativex\u00ae: Clinical Efficacy and Tolerability in the Treatment of Symptoms of Multiple Sclerosis and Neuropathic Pain","volume":"7","author":"Barnes","year":"2006","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_37","unstructured":"Office of the Commissioner (2024, May 13). FDA Approves First Drug Comprised of an Active Ingredient Derived from Marijuana to Treat Rare, Severe Forms of Epilepsy, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms."},{"key":"ref_38","unstructured":"Office of the Commissioner (2024, May 13). FDA Regulation of Cannabis and Cannabis-Derived Products: Q&A, Available online: https:\/\/www.fda.gov\/news-events\/public-health-focus\/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd."},{"key":"ref_39","unstructured":"O\u2019Donnell, B., Meissner, H., and Gupta, V. (2024, May 13). Dronabinol, StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557531\/."},{"key":"ref_40","unstructured":"Throckmorton, D. (2024, May 13). FDA Role in Regulation of Cannabis Products, Available online: https:\/\/www.fda.gov\/media\/152407\/download."},{"key":"ref_41","unstructured":"(2014). Orphan Designation for Treatment of Dravet Syndrome (Standard No. EU\/3\/14\/1339). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/orphan-designations\/eu-3-14-1339."},{"key":"ref_42","unstructured":"European Medicines Agency (2024, May 07). European Medicines Agency Decision: P\/0110\/2022, Available online: https:\/\/www.ema.europa.eu\/en\/documents\/pip-decision\/p01102022-ema-decision-13-april-2022-acceptance-modification-agreed-paediatric-investigation-plan-cannabidiol-delta-9-tetrahydrocannabinol-sativex-emea-000181-pip01-08-m06_en.pdf."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/17425247.2020.1713087","article-title":"Permeation Enhancers in Transdermal Drug Delivery: Benefits and Limitations","volume":"17","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/ejp.818","article-title":"Transdermal Cannabidiol Reduces Inflammation and Pain-Related Behaviours in a Rat Model of Arthritis","volume":"20","author":"Hammell","year":"2015","journal-title":"Eur. J. Pain"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1038\/s41386-018-0050-8","article-title":"Unique Treatment Potential of Cannabidiol for the Prevention of Relapse to Drug Use: Preclinical Proof of Principle","volume":"43","author":"Kerr","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.pbb.2013.08.013","article-title":"Transdermal Delivery of Cannabidiol Attenuates Binge Alcohol-Induced Neurodegeneration in a Rodent Model of an Alcohol Use Disorder","volume":"111","author":"Liput","year":"2013","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Momekova, D., Danov, Y., Momekov, G., Ivanov, E., and Petrov, P. (2021). Polysaccharide Cryogels Containing \u03b2-Cyclodextrin for the Delivery of Cannabidiol. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13111774"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e2123930","DOI":"10.1001\/jamanetworkopen.2021.23930","article-title":"Safety and Tolerability of Transdermal Cannabidiol Gel in Children with Developmental and Epileptic Encephalopathies: A Nonrandomized Controlled Trial","volume":"4","author":"Scheffer","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e2220189","DOI":"10.1001\/jamanetworkopen.2022.20189","article-title":"Adjunctive Transdermal Cannabidiol for Adults with Focal Epilepsy: A Randomized Clinical Trial","volume":"5","author":"Berkovic","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s11689-022-09466-6","article-title":"A Randomized, Controlled Trial of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Fragile X Syndrome (CONNECT-FX)","volume":"14","author":"Hagerman","year":"2022","journal-title":"J. Neurodev. Disord."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jcis.2022.12.036","article-title":"Encapsulation of Cannabidiol in Oil-In-Water Nanoemulsions and Nanoemulsion-Filled Hydrogels: A Structure and Biological Assessment Study","volume":"634","author":"Demisli","year":"2023","journal-title":"J. Colloid Interface Sci."},{"key":"ref_52","first-page":"112560","article-title":"A Cannabidiol-Containing Alginate Based Hydrogel as Novel Multifunctional Wound Dressing for Promoting Wound Healing","volume":"134","author":"Zheng","year":"2021","journal-title":"Mater. Sci. Eng. C"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"121036","DOI":"10.1016\/j.ijpharm.2021.121036","article-title":"Development and Optimisation of Biopharmaceutical Properties of a New Microemulgel of Cannabidiol for Locally-Acting Dermatological Delivery","volume":"607","author":"Vanti","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Casiraghi, A., Musazzi, U.M., Centin, G., Franz\u00e8, S., and Minghetti, P. (2020). Topical Administration of Cannabidiol: Influence of Vehicle-Related Aspects on Skin Permeation Process. Pharmaceuticals, 13.","DOI":"10.3390\/ph13110337"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1211\/0022357022791","article-title":"Human Skin Permeation of \u03948-Tetrahydrocannabinol, Cannabidiol and Cannabinol","volume":"56","author":"Stinchcomb","year":"2004","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Radwan-Prag\u0142owska, J., Janus, \u0141., Pi\u0105tkowski, M., Sierakowska, A., Szajna, E., Mat\u00fdsek, D., and Bogda\u0142, D. (2021). Development of Stimuli-Responsive Chitosan\/ZnO NPs Transdermal Systems for Controlled Cannabidiol Delivery. Polymers, 13.","DOI":"10.3390\/polym13020211"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Khabir, Z., Partalis, C., Panchal, J.V., Deva, A., Khatri, A., and Garcia-Bennett, A. (2023). Enhanced Skin Penetration of Cannabidiol Using Organosilane Particles as Transdermal Delivery Vehicles. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15030798"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"120766","DOI":"10.1016\/j.ijpharm.2021.120766","article-title":"Development of a Novel Cannabinoid-Loaded Microemulsion towards an Improved Stability and Transdermal Delivery","volume":"604","author":"Park","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Nitecka-Buchta, A., Nowak-Wachol, A., Wachol, K., Walczy\u0144ska-Dragon, K., Olczyk, P., Batoryna, O., Kempa, W., and Baron, S. (2019). Myorelaxant Effect of Transdermal Cannabidiol Application in Patients with TMD: A Randomized, Double-Blind Trial. J. Clin. Med., 8.","DOI":"10.3390\/jcm8111886"},{"key":"ref_60","first-page":"93","article-title":"A Therapeutic Effect of Cbd-Enriched Ointment in Inflammatory Skin Diseases and Cutaneous Scars Clinical Trial","volume":"170","author":"Palmieri","year":"2019","journal-title":"Clin. Ter."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Emanet, M., and Ciofani, G. (2023). Ethosomes as Promising Transdermal Delivery Systems of Natural-Derived Active Compounds. Adv. NanoBiomed Res., 3.","DOI":"10.1002\/anbr.202300020"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-3-030-17355-5_5","article-title":"The Role of Excipients in the Microstructure of Topical Semisolid Drug Products","volume":"Volume 36","author":"Langley","year":"2019","journal-title":"The Role of Microstructure in Topical Drug Product Development"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Dragicevic, N., and Maibach, H.I. (2015). Percutaneous Penetration Enhancers Chemical Methods in Penetration Enhancement, Springer.","DOI":"10.1007\/978-3-662-47039-8"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3389\/fchem.2018.00271","article-title":"Combining Cellulose and Cyclodextrins: Fascinating Designs for Materials and Pharmaceutics","volume":"6","author":"Cova","year":"2018","journal-title":"Front. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Taokaew, S., Kaewkong, W., and Kriangkrai, W. (2023). Recent Development of Functional Chitosan-Based Hydrogels for Pharmaceutical and Biomedical Applications. Gels, 9.","DOI":"10.3390\/gels9040277"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Tomi\u0107, S.L., Babi\u0107 Radi\u0107, M.M., Vukovi\u0107, J.S., Filipovi\u0107, V.V., Nikodinovic-Runic, J., and Vukomanovi\u0107, M. (2023). Alginate-Based Hydrogels and Scaffolds for Biomedical Applications. Mar. Drugs, 21.","DOI":"10.3390\/md21030177"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Berenguer, D., Sosa, L., Alcover, M., Sessa, M., Halbaut, L., Guill\u00e9n, C., Fisa, R., Calpena-Campmany, A.C., and Riera, C. (2019). Development and Characterization of a Semi-Solid Dosage Form of Meglumine Antimoniate for Topical Treatment of Cutaneous Leishmaniasis. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11110613"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"121439","DOI":"10.1016\/j.ijpharm.2021.121439","article-title":"Skin Interaction, Permeation, and Toxicity of Silica Nanoparticles: Challenges and Recent Therapeutic and Cosmetic Advances","volume":"614","author":"Morais","year":"2022","journal-title":"Int. J. Pharm."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Patil, K.R., Mahajan, U.B., Unger, B.S., Goyal, S.N., Belemkar, S., Surana, S.J., Ojha, S., and Patil, C.R. (2019). Animal Models of Inflammation for Screening of Anti-Inflammatory Drugs: Implications for the Discovery and Development of Phytopharmaceuticals. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20184367"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"292","DOI":"10.4103\/0253-7613.157127","article-title":"A Study of the Mechanisms Underlying the Anti-Inflammatory Effect of Ellagic Acid in Carrageenan-Induced Paw Edema in Rats","volume":"47","author":"Ghorbanzadeh","year":"2015","journal-title":"Indian J. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5.4.1","DOI":"10.1002\/0471141755.ph0504s56","article-title":"Models of Inflammation: Carrageenan- or Complete Freund\u2019s Adjuvant-Induced Edema and Hypersensitivity in the Rat","volume":"56","author":"Fehrenbacher","year":"2012","journal-title":"Curr. Protoc. Pharmacol."},{"key":"ref_72","first-page":"97","article-title":"Crocin Alleviates the Local Paw Edema Induced by Histamine in Rats","volume":"2","author":"Tamaddonfard","year":"2012","journal-title":"Avicenna J. Phytomed."},{"key":"ref_73","first-page":"336","article-title":"Experimental Inflammation Models Created in Laboratory Animals","volume":"16","author":"Akpinar","year":"2021","journal-title":"Atat\u00fcrk Univ. J. Vet. Sci."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s12079-021-00652-0","article-title":"A Modular Map of Bradykinin-Mediated Inflammatory Signaling Network","volume":"16","author":"Rex","year":"2021","journal-title":"J. Cell Commun. Signal."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Coura, C.O., Souza, R.B., Rodrigues, J.A.G., de Sousa Oliveira Vanderlei, E., de Ara\u00fajo, I.W.F., Ribeiro, N.A., Frota, A.F., Ribeiro, K.A., Chaves, H.V., and Pereira, K.M.A. (2015). Mechanisms Involved in the Anti-Inflammatory Action of a Polysulfated Fraction from Gracilaria cornea in Rats. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0119319"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Xu, M., Chen, Q., Fan, R., Wang, J., and Li, Y. (2019). Anti-Inflammation Effect of Small Molecule Oligopeptides Prepared from Panax ginseng C. A. Meyer in Rats. Molecules, 24.","DOI":"10.3390\/molecules24050858"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.intimp.2004.04.007","article-title":"Lipopolysaccharide-Induced Paw Edema Model for Detection of Cytokine Modulating Anti-Inflammatory Agents","volume":"4","author":"Vajja","year":"2004","journal-title":"Int. Immunopharmacol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/PL00005345","article-title":"The Inflammatory Reaction Induced by Formalin in the Rat Paw","volume":"359","author":"Damas","year":"1999","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/11\/5858\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:49:18Z","timestamp":1760107758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/11\/5858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,28]]},"references-count":78,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["ijms25115858"],"URL":"https:\/\/doi.org\/10.3390\/ijms25115858","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,28]]}}}